東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Complementary and Alternative Medicine." ]

切換: 標籤 | MARC模式 | ISBD

Plant-based therapeutics. = cannabis...

Ross, Ivan A.

FindBook

Google Book

Amazon

博客來

Plant-based therapeutics. = cannabis sativa /. Volume 1

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Plant-based therapeutics./ by Ivan A. Ross.
其他題名:	cannabis sativa /
作者:	Ross, Ivan A.
出版者:	Cham :Springer International Publishing : : 2023.,
面頁冊數:	xxi, 657 p. :ill., digital ;24 cm.
內容註:	Chapter 1 The History of Cannabis -- Chapter 2 The Bioactive Components of Plants -- Chapter 3 Chemical Constituents of Cannabis -- Chapter 4 The Bioactive Components of Cannabis -- Chapter 5 Neurological Effects of Cannabis -- Chapter 6 Psychotropic Effects of Cannabis -- Chapter 7 The Analgesic effects of Cannabis -- Chapter 8 Cannabis and Perinatal Development -- Chapter 9 Cannabis and Multiple Sclerosis -- Chapter 10 Cannabis and Cancer -- Chapter 11 Cannabis and Parkinson's disease -- Chapter 12 Cannabis and the Skin -- Chapter 13 Antiviral Activities of Cannabis -- Chapter 14 Alkaline Phosphatase Stimulation.
Contained By:	Springer Nature eBook
標題:	Cannabis - Therapeutic use. -
電子資源:	https://doi.org/10.1007/978-3-031-35155-6
ISBN:	9783031351556

Plant-based therapeutics. = cannabis sativa /. Volume 1
Ross, Ivan A.

Plant-based therapeutics.cannabis sativa /Volume 1[electronic resource] :by Ivan A. Ross. - Cham :Springer International Publishing :2023. - xxi, 657 p. :ill., digital ;24 cm.

Chapter 1 The History of Cannabis -- Chapter 2 The Bioactive Components of Plants -- Chapter 3 Chemical Constituents of Cannabis -- Chapter 4 The Bioactive Components of Cannabis -- Chapter 5 Neurological Effects of Cannabis -- Chapter 6 Psychotropic Effects of Cannabis -- Chapter 7 The Analgesic effects of Cannabis -- Chapter 8 Cannabis and Perinatal Development -- Chapter 9 Cannabis and Multiple Sclerosis -- Chapter 10 Cannabis and Cancer -- Chapter 11 Cannabis and Parkinson's disease -- Chapter 12 Cannabis and the Skin -- Chapter 13 Antiviral Activities of Cannabis -- Chapter 14 Alkaline Phosphatase Stimulation.

By examining historical applications of the compounds found in plants, this five-volume series serves as a reference for quality assurance, research, product development, and regulatory guidance of the compounds found in plant-based medicines. This work supports the growing consumers' interest in herbal medicine for wellness and health. Plant-Based Therapeutics, Volume 1: Cannabis sativa, the first in the series, covers a unique plant species and provides the framework to integrate its evidence-based scientific discoveries with healthcare therapies. Cannabis has been used in religious ceremonies and medical purposes for thousands of years. Cannabidiol (CBD), the main non-psychoactive component of Cannabis, was isolated in the 1940s, and its structure was established in the 1960s. In 1964 tetrahydrocannabinol (THC), the psychoactive component, was isolated. Cannabis has more than 500 components, of which 104 cannabinoids have been identified. Two of them, THC and CBD, have been the primary components of scientific investigations. They were approved by the FDA for chemotherapy-induced nausea and vomiting in 1985; for appetite stimulation in wasting conditions, such as AIDS, in 1992, and in 2018 for treating two forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Beyond the indications for which cannabinoids are FDA-approved, the evidence reveals that cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Thus, other constituents of Cannabis are extremely promising either as individual compounds or their potential synergistic or entourage effects in the treatment of numerous medical conditions.

ISBN: 9783031351556

Standard No.: 10.1007/978-3-031-35155-6doiSubjects--Topical Terms:

895485
Cannabis
--Therapeutic use.

LC Class. No.: RM666.C266

Dewey Class. No.: 615.7827

Plant-based therapeutics. = cannabis sativa /. Volume 1
LDR:03423nmm a2200325 a 4500 001 2333514
003 DE-He213
005 20230808023038.0
006 m d
007 cr nn 008maaau
008 240402s2023 sz s 0 eng d
020 $a 9783031351556 $q (electronic bk.)
020 $a 9783031351549 $q (paper)
024 7 $a 10.1007/978-3-031-35155-6 $2 doi
035 $a 978-3-031-35155-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RM666.C266
072 7 $a PST $2 bicssc
072 7 $a SCI011000 $2 bisacsh
072 7 $a PST $2 thema
082 0 4 $a 615.7827 $2 23
090 $a RM666.C266 $b R824 2023
100 1 $a Ross, Ivan A. $3 891279
245 1 0 $a Plant-based therapeutics. $n Volume 1 $h [electronic resource] : $b cannabis sativa / $c by Ivan A. Ross.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a xxi, 657 p. : $b ill., digital ; $c 24 cm.
505 0 $a Chapter 1 The History of Cannabis -- Chapter 2 The Bioactive Components of Plants -- Chapter 3 Chemical Constituents of Cannabis -- Chapter 4 The Bioactive Components of Cannabis -- Chapter 5 Neurological Effects of Cannabis -- Chapter 6 Psychotropic Effects of Cannabis -- Chapter 7 The Analgesic effects of Cannabis -- Chapter 8 Cannabis and Perinatal Development -- Chapter 9 Cannabis and Multiple Sclerosis -- Chapter 10 Cannabis and Cancer -- Chapter 11 Cannabis and Parkinson's disease -- Chapter 12 Cannabis and the Skin -- Chapter 13 Antiviral Activities of Cannabis -- Chapter 14 Alkaline Phosphatase Stimulation.
520 $a By examining historical applications of the compounds found in plants, this five-volume series serves as a reference for quality assurance, research, product development, and regulatory guidance of the compounds found in plant-based medicines. This work supports the growing consumers' interest in herbal medicine for wellness and health. Plant-Based Therapeutics, Volume 1: Cannabis sativa, the first in the series, covers a unique plant species and provides the framework to integrate its evidence-based scientific discoveries with healthcare therapies. Cannabis has been used in religious ceremonies and medical purposes for thousands of years. Cannabidiol (CBD), the main non-psychoactive component of Cannabis, was isolated in the 1940s, and its structure was established in the 1960s. In 1964 tetrahydrocannabinol (THC), the psychoactive component, was isolated. Cannabis has more than 500 components, of which 104 cannabinoids have been identified. Two of them, THC and CBD, have been the primary components of scientific investigations. They were approved by the FDA for chemotherapy-induced nausea and vomiting in 1985; for appetite stimulation in wasting conditions, such as AIDS, in 1992, and in 2018 for treating two forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Beyond the indications for which cannabinoids are FDA-approved, the evidence reveals that cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Thus, other constituents of Cannabis are extremely promising either as individual compounds or their potential synergistic or entourage effects in the treatment of numerous medical conditions.
650 0 $a Cannabis $x Therapeutic use. $3 895485
650 0 $a Medicinal plants. $3 545848
650 1 4 $a Plant Science. $3 3531282
650 2 4 $a Complementary and Alternative Medicine. $3 3538431
650 2 4 $a Pharmacology. $3 634543
650 2 4 $a Medicinal Chemistry. $3 892420
650 2 4 $a Physiology. $3 518431
650 2 4 $a Agriculture. $3 518588
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-35155-6
950 $a Biomedical and Life Sciences (SpringerNature-11642)